Gilead Sciences, Inc. (GILD) 2024 10-K Earnings Analysis
Gilead Sciences, Inc.2024 Earnings Analysis
76/100
Gilead's FY2024 GAAP result understates the business it actually ran: $28.8B revenue, only $0.48B reported net income after acquisition-accounting charges, but $10.8B operating cash flow and $10.3B free cash flow from a still-dominant HIV franchise. This is a cash-rich biopharma using HIV economics to fund an oncology and liver-disease rebuild. The investment question is whether that reinvestment produces a second durable franchise before the HIV portfolio reaches the later stages of its patent cycle.
Filing analysis
Gilead Sciences, Inc. 2024 10-K Analysis
This page reads Gilead Sciences, Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 76/100, or grade C.
GILD Earnings Quality
The earnings-quality module scores 72/100, with Gross Margin: 78.3%, CF/Net Income (skewed): 22.6x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
GILD Economic Moat Analysis
The moat-strength module scores 82/100, with HIV Franchise: Category leadership, Oncology Build: Trodelvy + Yescarta. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
GILD Free Cash Flow vs Net Income
CF/Net Income (skewed): 22.6x, Operating Cash Flow: $10.8B is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 80/100. For the diagnostic, start with cash flow vs net income.
GILD Key Risks from the Annual Report
The risk module scores 70/100, with HIV LOE Horizon: Mid-horizon, IRA Drug Pricing: Structural. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is GILD a High Quality Earnings Stock?
Based on this 2024 filing, GILD needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 72/100. This is a research screen, not investment advice.
Read the report first
Understand Gilead Sciences, Inc. first, then decide if it belongs on your watchlist
The GILD score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep GILD with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the GILD report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 78.3% reflects the branded-biopharma cost structure. HIV-franchise products (Biktarvy, Descovy) plus HCV (Epclusa/Vosevi) and oncology (Trodelvy) are the principal margin contributors.
Per the FY2024 cash flow statement, OCF of $10.8B against NI of $0.48B produces a 22.6x CF/NI ratio — the spread dominated by non-cash IPRD charges and intangible-asset amortization from the 2024 CymaBay (seladelpar for PBC per the closing press release) and Terray acquisitions plus residual Immunomedics-acquired-Trodelvy amortization.
Per the FY2024 cash flow statement, OCF of $10.8B is the clean through-cycle earning-power read. The GAAP net income is distorted by acquisition-accounting charges that do not reflect cash dynamics.
Per the FY2024 product-revenue disclosures, revenue is dominated by HIV (Biktarvy, Descovy, Genvoya, Odefsey), supplemented by liver disease (Epclusa, Vosevi, Seladelpar/Livdelzi per the 2024 launch), and oncology (Trodelvy, Yescarta, Tecartus — the CAR-T cell-therapy franchise from Kite Pharma acquisition per prior 10-Ks).
Earnings quality scores 72/100. Gilead's FY2024 numbers are readable only if cash flow is treated as the primary truth source. Gross margin stayed very high, but reported earnings were suppressed by acquisition-accounting charges tied to the 2024 deal activity. The company therefore looks less like a low-profit pharma operator than like a high-cash legacy franchise reinvesting through the income statement.
Moat Strength
Per the FY2024 10-K HIV product disclosures, Biktarvy is the HIV-treatment-product revenue anchor. Gilead's HIV portfolio spans treatment (Biktarvy, Genvoya, Odefsey, Descovy) and PrEP prevention (Descovy). The franchise has a disclosed path toward the lenacapavir-based Sunlenca long-acting regimen per the publicly-announced Phase-3 readouts and FDA-label updates.
Per the FY2024 oncology product disclosures, Trodelvy (sacituzumab govitecan, from Immunomedics 2020 acquisition per the closing press release) and the Yescarta/Tecartus CAR-T portfolio (from the 2017 Kite Pharma acquisition per prior 10-Ks) form the oncology franchise. Label expansions have been disclosed across successive product-launch press releases.
Per the FY2024 10-K liver-disease product disclosures, Gilead's HCV portfolio (Epclusa, Vosevi, Harvoni) generated historical revenue that has since normalized; the 2024 CymaBay acquisition added seladelpar (now branded Livdelzi) for primary biliary cholangitis per the closing press release.
Goodwill of $8B on $59B assets equals 14.1% per the FY2024 balance sheet — reflects the historical Kite Pharma (2017) and Immunomedics (2020) acquisitions per the respective closing press releases plus the 2024 CymaBay transaction.
Moat strength scores 82/100. Gilead's moat is narrower than it was in the HCV era but still unusually cash generative because HIV remains a scale franchise with product breadth, payer familiarity, and a credible long-acting extension path. The rest of the moat story is unfinished: oncology and liver disease are meaningful, but they still read more like a build-out than a fully entrenched second pillar.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $10.3B (OCF $10.8B minus capex $0.5B) supports the dividend and the share-repurchase program plus M&A disclosed in the capital-return section.
Per the FY2024 cash flow statement, $0.5B capex on $28.8B revenue equals 1.8% — the asset-light biopharma operating model where manufacturing is largely outsourced or runs on prior facilities-plant investments.
Per the FY2024 proxy and capital-return disclosures, Gilead maintains a quarterly dividend that has been periodically raised and a sizable share-repurchase program.
Per Gilead's 2024 CymaBay closing press release (approximately $4.3B), the seladelpar-for-PBC asset (now Livdelzi) was added. The Terray Therapeutics collaboration per the 2024 partnership announcement adds computational-AI-chemistry capability.
Capital allocation scores 80/100. Gilead is allocating cash from a mature franchise into portfolio renewal rather than simply maximizing near-term payout. That is why the income statement looks messier than the cash statement. The analytical challenge is to decide whether management is buying enough future optionality to justify absorbing CymaBay-style charges and continued oncology investment.
Key Risks
Per the FY2024 10-K patent-expiry disclosures, key HIV products (TAF-based regimens including Biktarvy components) face patent expirations on a staggered multi-year horizon. Management's long-acting HIV pipeline (Sunlenca-based regimens) per publicly-announced Phase-3 readouts is the strategic response.
Per HHS CMS's public announcements under the Inflation Reduction Act, Medicare Part D and Part B drug-price negotiation affects specific Gilead products on successive selection lists. Disclosed pricing impacts flow through segment revenue per the FY2024 risk-factor disclosures.
Per the FY2024 Risk Factors and publicly-reported Trodelvy Phase-3 readouts, Trodelvy label-expansion trials have shown mixed outcomes including some missed primary endpoints in lung-cancer indications. Future label extensions depend on trial readouts disclosed via ClinicalTrials.gov and company press releases.
Per the FY2024 Kite Pharma segment MD&A and CAR-T industry trade press, Yescarta/Tecartus face competition from BMS's Breyanzi/Abecma (partnered with 2seventy bio), Novartis's Kymriah, and emerging bispecific antibodies (e.g., Epcoritamab, Glofitamab per the respective FDA-approval disclosures). Competitive dynamics shape the CAR-T-segment revenue trajectory.
Risk profile scores 70/100 (higher = safer). Per the FY2024 10-K, the main watch-items are (1) staggered HIV patent-expiry horizon with the long-acting Sunlenca-pipeline response per publicly-announced Phase-3 readouts, (2) Medicare IRA drug-price-negotiation exposure per HHS CMS public disclosures, (3) oncology-trial readouts for Trodelvy label expansions disclosed via ClinicalTrials.gov and company press releases, and (4) CAR-T competitive dynamics across Yescarta/Tecartus vs. Breyanzi/Kymriah and the bispecific-antibody class per industry trade press.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.